JPRN-jRCT2021200039进行中（未招募）3 期
A multi-center, randomized, double-blind, placebocontrolled, parallel group, phase III study to evaluate the efficacy and safety of LNP023 in primary IgA nephropathy patients
Yamada Hiroyuki0 个研究点目标入组 30 人开始时间: 2021年3月1日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Male and female patients >= 18 years of age with an eGFR level and biopsy-confirmed IgA nephropathy as follows:
- •- For patients eGFR >= 45ml/min/1.73m2, a qualifying biopsy performed within the last 5 years is required.
- •- For patients with eGFR 30 to <45ml/min/1.73m2, a qualifying biopsy performed within 2 years with < 50% tubulointerstitial fibrosis is required.
- •- For patients with eGFR 20 to <30ml/min/1.73m2, a qualifying biopsy performed at any time.
- •In all cases, if a historical biopsy is not available, one may be performed during screening.
- •- Proteinuria due to primary diagnosis of IgA nephropathy as assessed at screening by UPCR >=1 g/g (113 mg/mmol) sampled from FMV or 24h urine collection, as well as at the completion of the run-in period by UPCR >=1 g/g (113 mg/mmol) calculated as the mean of two 24h urine collections obtained within 14 days of each other at baseline.
- •- Vaccination against Neisseria meningitidis infection is required prior to the start of study treatment. If the patient has not been previously vaccinated, or if a booster is required, vaccine should be given according to local regulations at least 2 weeks prior to first study drug administration. If study treatment has to start earlier than 2 weeks post vaccination, prophylactic antibiotic treatment should be initiated.
- •- If not previously vaccinated, vaccination against Streptococcus pneumoniae and Haemophilus influenzae infections should be given, if available and according to local regulations, at least 2 weeks prior to first study drug administration. If study treatment has to start earlier than 2 weeks post vaccination, prophylactic antibiotic treatment should be initiated.
- •- All patients must have been on supportive care including stable dose regimen of ACEi or ARB at either the locally approved maximal daily dose or the maximally tolerated dose (per investigators' judgment) for at least 90 days before first study drug administration. In addition, if patients are taking diuretics or other antihypertensive therapy, the doses should also be stabilized for at least 90 days prior to the first dosing of study treatment.
排除标准
- •- Any secondary IgAN as defined by the investigator; secondary IgAN can be associated with cirrhosis, celiac disease, Human Immunodeficiency Virus (HIV) infection, herpetiformis, seronegative arthritis, small-cell carcinoma, lymphoma, disseminated tuberculosis, bronchiolitis obliterans, and inflammatory bowel disease, familial mediterranean fever, etc.
- •- Sitting office SBP >140 mmHg or DBP >90 mmHg at the randomization visit
- •- Patients previously treated with immunosuppressive or other immunmodulatory agents such as but not limited to cyclophosphamide, rituximab, infliximab, eculizumab, canakinumab, hydroxychloroquine, mycophenolate mofetil (MMF) or mycophenolate sodium (MPS), cyclosporine, tacrolimus, sirolimus, everolimus, or systemic corticosteroids exposure (>10 mg/d prednisone/prednisolone equivalent) within 90 days (or 180 days for rituximab) prior to first study drug administration
- •- Prior use of LNP023 or prior enrollment in any other LNP023 clinical trial where study drug was taken, including matching placebo
- •- History of recurrent invasive infections caused by encapsulated organisms, such as meningococcus and pneumococcus.
- •- Active systemic bacterial, viral (including COVID-19) or fungal infection within 14 days prior to study drug administration.
- •Other protocol-defined inclusion/exclusion criteria may apply.
研究者
相似试验
进行中（未招募）
1 期
A multi-center, randomized, double-blind, placebocontrolled clinical trial of deferasirox in patients with myelodysplastic syndromes (low/int-1 risk) and transfusional iron overload - TELESTOmyelodysplastic syndromes(low/int-1 risk)MedDRA version: 12.1Level: LLTClassification code 10019613Term: HemosiderosisEUCTR2009-012418-38-ITOVARTIS FARMA630
进行中（未招募）
不适用
A multi-center, randomized, double-blind, placebocontrolled, two-period cross-over study to assess the effect of 50 µg inhaled NVA237 on exercise endurance in patients with moderate to severe COPD - NDChronic obstructive pulmonary disease (COPD)MedDRA version: 9.1Level: SOCClassification code 10038738EUCTR2010-018597-20-ITOVARTIS FARMA80
进行中（未招募）
不适用
A multi-center, randomized, double-blind, placebocontrolled clinical trial to evaluate the effect of 52 weeks treatment with vildagliptin on left ventricular function in patients with type 2 diabetes and congestive heart failure - NDtype 2 diabetes and congestive heart failureMedDRA version: 9.1Level: LLTClassification code 10012647Term: Diabetic cardiomyopathyEUCTR2008-005012-41-ITOVARTIS FARMA246
招募中
3 期
A multi-center, randomized, double-blind, placebocontrolled, parallel group, phase III study to evaluate the efficacy and safety of LNP023 in primary IgA nephropathy patientsIgA kidney diseaseIgAN10029149NL-OMON56184ovartis3
招募中
3 期
Coronary computed tomography study to assess the effect of inclisiran on atherosclerotic plaque progression in participants with a diagnosis of nonobstructive coronary artery disease without previous cardiovascular eventsCoronary Artery DiseaseJPRN-jRCT2071230017Hirano Takamitsu5